#None #Las Vegas #Minimally Invasive #BPH Treatment #Butterfly Medical

Introduction

Butterfly Medical, a medical device innovator focused on improving the quality of life for those suffering from Benign Prostatic Hyperplasia (BPH), has unveiled new research indicating the effectiveness of its minimally invasive prostatic retraction device. This announcement comes ahead of its presentations at the American Urological Association's Annual Conference (AUA 2025) taking place in Las Vegas from April 26 to 29.

Device Overview

With a pressing need for effective BPH treatments that do not require extensive surgical procedures, Butterfly Medical has developed a novel implantable device designed to alleviate the distressing symptoms associated with this common condition. The unique aspect of this device is that it does not necessitate the cutting or removal of tissue, making it a reversible and less invasive option for patients.

The device can be installed in various healthcare settings and is intended to be administered under local anesthesia, thus minimizing recovery time while allowing for potential future interventions if required. Butterfly Medical has already garnered CE Mark Approval for their device and is currently participating in a pivotal clinical study in the United States.

Positive Study Findings

According to Patrick MacCarthy, CEO of Butterfly Medical, the data collected has shown marked, sustained improvements in the symptoms of lower urinary tract issues caused by BPH. Furthermore, the device's effectiveness has been demonstrated over a five-year period post-treatment, giving hope to many patients seeking long-term relief.

The findings to be showcased at the AUA conference will encompass two key presentations:
1. Oral Presentation - Butterfly Pivotal Trial
- This presentation will cover a prospective, blinded, multicenter study evaluating the Butterfly prostatic retraction device in men experiencing lower urinary tract symptoms due to BPH. It will be delivered by Dr. Bilal Chughtai, Associate Professor of Urology at Northwell Health, on April 26, 2025.
2. Poster Presentation - 5-Year Follow-Up
- Focused on a multicenter, prospective pilot study (BM-011-LT), this poster presentation by Dr. Ran Katz, Head of the Department of Urology at Bar Ilan University, will discuss results from a five-year follow-up of users of the Butterfly device. The session is scheduled for the same day as the oral presentation.

Impact and Future Directions

Butterfly Medical's presentation at AUA 2025 is expected to underscore the significant clinical implications of the device and its potential to be a leading option for BPH management moving forward. As the medical community grapples with the limitations of current treatment options, the results from Butterfly Medical's research could pave the way for broader acceptance of minimally invasive techniques in urology.

By providing compelling evidence of effective, long-term management of BPH symptoms through their innovative device, Butterfly Medical aims to redefine the patient experience, offering not just a temporary solution, but a holistic approach to managing this prevalent condition.

Conclusion

As BPH continues to impact a growing demographic, particularly among aging men, the advancements made by Butterfly Medical come at a crucial time. Their commitment to enhancing patient outcomes through innovative medical technology serves to highlight the ongoing evolution of healthcare solutions in urology. Attendees of AUA 2025 will be among the first to witness the extensive research supporting this next-generation device, marking a significant step towards better male health management.

For additional information regarding Butterfly Medical and updates from AUA 2025, interested parties are encouraged to visit Butterfly Medical's official site or follow their insights on LinkedIn.